Stabilized lipid formulation of apoptosis promoter
View Patent ↗An orally deliverable pharmaceutical composition comprises a Bcl-2 family protein inhibitory compound, e.g., ABT-263, a heavier-chalcogen antioxidant and a substantially non-aqueous lipid carrier, wherein said compound and said antioxidant are in solution in the carrier. The composition is suitable for oral administration to a subject in need thereof for treatment of a disease characterized by overexpression of one or more anti-apoptotic Bcl-2 family proteins, for example cancer.
1. A pharmaceutical composition in a form of a liquid solution comprising about 5% to about 20% by weight ABT-263 free base, about 15% to about 60% by weight phosphatidylcholine, about 7% to about 30% by weight medium-chain triglycerides, about 7% to about 30% by weight medium-chain mono- and di-glycerides, about 7% to about 30% polysorbate 80 surfactant, about 0.02% to about 0.2% by weight sodium or potassium metabisulfite, about 0.003% to about 0.01% EDTA or salt thereof, and about 0.2% to about 0.8% water.
2. The composition of claim 1 , further comprising a capsule shell wherein said liquid solution is encapsulated.
3. The composition of claim 2 , wherein the liquid solution consists essentially of about 5% to about 20% by weight ABT-263 free base, about 15% to about 60% by weight phosphatidylcholine, about 7% to about 30% by weight medium-chain triglycerides, about 7% to about 30% by weight medium-chain mono- and diglycerides, about 7% to about 30% polysorbate 80 surfactant, about 0.02% to about 0.2% by weight sodium or potassium metabisulfite, about 0.003% to about 0.01% EDTA or salt thereof, and about 0.2% to about 0.8% water.
4. The composition of claim 2 , comprising a size 0 hard gelatin capsule shell having encapsulated therewithin a liquid solution that comprises about 50 mg ABT-263 free base, about 150 mg phosphatidylcholine, about 75 mg medium-chain triglycerides, about 90 mg medium-chain mono- and diglycerides, about 90 mg polysorbate 80 surfactant, about 0.25 mg sodium or potassium metabisulfite, about 0.025 mg EDTA or salt thereof, and about 2.5 mg water.